- 7% increase in total waste produced despite increase in recycling
- Increased direct emissions (Scope 1) of 11.5% due to increased fuel consumption
- Potential unethical business practices
- Loss of margins due to unexpected/unmanaged disruptions in the value chain
- Loss of/reduced attractiveness to talent due to failure to ensure equality for all
- Potential unethical business practices (e.g., in animal welfare, lack of transparency in marketing) with market and/or regulatory repercussions
- Failure to apply adequate due diligence measures, resulting in human rights violations within the corporate value chain (child/forced labor)
- Inability to address new potential pandemics, originating from neglected tropical diseases (NTDs) and/or other potential widespread dangerous diseases, through adequate resources and R&D strategies
- Lawsuits and product recalls due to unwanted/unexpected side effects and/or unsafe levels of hazardous ingredients
- Negative effects on the health resilience of communities due to the intake of pharmaceutical substances
Angelini Pharma S.p.A.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Angelini Pharma S.p.A. disclosed greenhouse gas emissions of 16.8K tCO2eq (Scope 1 & 2). By scope: Scope 1: 15.1K tCO2eq; Scope 2: 6.2K tCO2eq (market-based). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
16.8K tCO2eq (Scope 1 & 2)
2023
Water Usage
52.0 megaliters
2023
Waste
11.7K tons
2023
Energy Use
335.4K GJ
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 15.1K tCO2eq |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 6.2K tCO2eq (market-based) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 16.8K tCO2eq (Scope 1 & 2) |
| 2022 | 15.0K tCO2e/year (Scope 1 and 2) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced total water withdrawal by 10% (2023 vs 2022)
- Achieved a 29% increase in waste directed to recycling, reuse and recovery (2023 vs 2022)
- Launched carbon footprint calculation
- Started Life Cycle Assessment process on five brands
- Participation in LIFE-GREENAPI project to find more innovative and environmentally friendly ways to produce active pharmaceutical ingredients
- Ancona plant recorded a value of 28.87 toe/million pieces produced, a 28.4% decrease compared to 2022
🎯 Climate & Sustainability Targets
📅 Medium-term
- Climate: 100% renewable purchased electricity (Italy) by 2024
- Climate: 100% renewable purchased electricity on climate change (all Angelini Pharma) by 2026
- Waste & circularity: -90% industrial waste to landfill by 2028
- Waste & circularity: 100% new products rolled out / EcoDesign considerations by 2030
- Well-being: Engagement rate ≥75 by 2030
🔭 Long-term
- Climate: Reduce GHG emissions in line with Paris Agreement by 2030
🌱 ESG Focus Areas
PlanetPeoplePatients & CommunityEcosystemsProduct InnovationGovernance